MEIOB: A Potential Drug Target for Neurological Disorders (G254528)

Target Name: MEIOB

NCBI ID: G254528

MEIOB

MEIOB: A Potential Drug Target for Neurological Disorders

MEIOB (MEIOB_HUMAN) is a protein that is expressed in the nervous system and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. As a drug target or biomarker, MEIOB is of great interest to researchers because it provides a target for the development of new treatments for these disorders.

One of the key challenges in the development of new treatments for neurological disorders is the difficulty of targeting the underlying causes of the disease. This is because many of these disorders are complex and involve the interplay of multiple factors, making it difficult to identify the specific target that needs to be addressed. In addition, the development of new treatments often requires a long and expensive process of preclinical testing and clinical trials, which can be time-consuming and costly.

One way to address these challenges is to focus on identifying biomarkers that can be used to diagnose and monitor the progression of the disease. By identifying biomarkers, researchers can identify a specific target that can be targeted with new treatments, which can help to improve the treatment outcomes.

MEIOB is an example of a biomarker that has the potential to be used as a drug target or biomarker in the treatment of neurological disorders. It is a protein that is expressed in the nervous system and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease.

Research has shown thatMEIOB is involved in the formation of axoninitial segments (ASCs) in the nervous system, which are the initial stage of the development of neurons. ASCs are critical for the formation and maintenance of the nervous system, and are involved in many important functions, including the transmission of signals and the regulation of the environment.

In addition, research has shown thatMEIOB is involved in the regulation of the microtubules of the neurons, which are the structural elements that allow the neurons to transport material to and from their axons. Microtubules are made up of a protein called tau, which is involved in the regulation of the microtubules of the neurons.

MEIOB has also been shown to be involved in the regulation of the levels of a protein called synaptophysin, which is involved in the formation and maintenance of synapses, the structures that allow neurons to communicate with each other.

In conclusion, MEIOB is a protein that has the potential to be used as a drug target or biomarker in the treatment of neurological disorders. Its involvement in the formation and regulation of ASCs, microtubules, and synaptophysin, suggests that it may be a useful target for new treatments for a variety of neurological disorders. Further research is needed to determine the exact role of MEIOB in the development and progression of neurological disorders, as well as its potential as a drug target or biomarker.

Protein Name: Meiosis Specific With OB-fold

Functions: Single-stranded DNA-binding protein required for homologous recombination in meiosis I. Required for double strand breaks (DSBs) repair and crossover formation and promotion of faithful and complete synapsis. Not required for the initial loading of recombinases but required to maintain a proper number of RAD51 and DMC1 foci after the zygotene stage. May act by ensuring the stabilization of recombinases, which is required for successful homology search and meiotic recombination. Displays Single-stranded DNA 3'-5' exonuclease activity in vitro

The "MEIOB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEIOB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets